ID: MRFR/Pharma/2493-CR | 153 Pages | Author: Kinjoll Dey | August 2017
Halitosis Treatment Market Size was valued at USD 3.9 Billion in 2022. The Halitosis Treatment market industry is projected to grow from USD 4.37 Billion in 2023 to USD 10.91 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.12% during the forecast period (2023 - 2032).The market is expanding because to the ageing population as well as concerns about chronic diseases such diabetes, liver disease, lungs disease, and liver failure are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for halitosis treatment is being driven by the rising treatment. Further factors driving the market's expansion include the increased incidence of periodontal disorders, rising alcohol and tobacco usage, tonsillitis, and inflammation of the nose, throat, and sinuses. Halitosis is believed to be the third most prevalent cause for seeing a dentist, after periodontal disease and dental caries, according to a study titled "The Prevalence and Determinant Factors of Oral Halitosis in Northwest Ethiopia: A Cross-Sectional Study" released by Dovepress in 2021. Between 22% and 50% of individuals worldwide reported having halitosis. Between 22% and 50% of individuals worldwide reported having halitosis. In addition, according to another article titled "Say Ahhh: Experience and Views on Halitosis Management in the General Public in Victoria, Australia," published in August 2021 by the International Dental Journal, 8% to 10% of cases of halitosis are caused by extraoral factors, while up to 90% are caused by intraoral sources, such as tongue coating or periodontitis. Without any intraoral causes of halitosis, a patient may suffer from systemic, metabolic, or genetic diseases. As a result, a key element anticipated to influence halitosis diagnosis and therapy shortly is the rising incidence of the condition worldwide.
Additionally, gum (periodontal) disease, closely related to halitosis, may show warning signs such as chronic foul breath or an unpleasant taste in the mouth. The prevalence of total periodontitis and stage III/IV periodontitis was 85.4% and 48.5%, respectively, according to a study titled "Periodontal Disease Prevalence, Extent, and Risk Associations in Untreated Individuals" that was released in January 2022 by the AAP and the EFP. 78.4% and 31.1%, respectively, of people had moderate-to-severe periodontitis, according to the CDC/AAP. Therefore, it is anticipated that the rising frequency of periodontal disorders will propel market expansion during the study period. Halitosis is a widespread problem worldwide where severe instances only affect 5% of the population, but intermediate cases are common. The market is growing as the number of persons with halitosis increases and public knowledge of the condition and its treatment increases. In the US, almost 80 million people spend more than USD 10.75 billion yearly on dental care items. Thus, driving the Halitosis Treatment market revenue.
Based on indication, the Halitosis Treatment market segmentation includes respiratory, liver, kidney, gastrointestinal, systemic, and others. The liver segment dominated the market, accounting for 35% of market revenue. Trimethylamine is more prevalent in cirrhotic patients, which leads to bad breath. One of the odd symptoms of fatty liver disease is "breath of the dead." The Fetor hepaticus, often known as the breath of the dead, is a lingering odor that differs from typical breath. Hepatitis and liver failure are intimately connected to fetor hepaticus.
Organ-related bad breath is typically caused by a sickness or food that interacts with blood levels and generates an odor. Since liver illnesses and bad breath are frequently linked, the rise in liver diseases is anticipated to accelerate the segment's growth throughout the projected period.
Based on diagnostic tests, the Halitosis Treatment market segmentation includes an altimeter, gas chromatography, BANA test, and Β-galactosidase activity assay. The BANA test segment dominated the market. The BANA test assesses the proteolytic activity of certain oral anaerobes that contribute to oral malodor. It refers to the enzymatic breakdown of [N-benzoyl-dL-arginine-2-napthylamide]. Treponema denticola, Prophyromona gingivitis, and Bacteroides forsythias (Red complex) are a few bacteria that create waste products that are highly odiferous and, as a result, contribute to foul breath. The N-benzoyl enzyme is destroyed when a patient's saliva sample containing these bacteria is added to the BANA testing chemical. The test substance changes color due to this biodegradation, indicating a successful response.
The Halitosis Treatment market segmentation, based on Drug Treatment, includes antacids, antiseptics, ranitidine, and others. The antacids generated the most income. Antacids are frequently used since they are affordable and help to reduce the discomfort, irritation, edema, and inflammation brought on by heartburn. Additionally, several product advancements, such as creating powerful and safe raft-forming antacids that offer improved efficacy and a longer duration of action, are boosting the market's expansion. The market is expected to develop due to the increasing use of chewable tablets in various flavors that are convenient to store, deliver the right dosage, and enhance patient adherence.
Figure 1: Halitosis Treatment Market, by Drug Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Halitosis Treatment market area will dominate this market due to an increase in periodontal disorders, a rise in halitosis prevalence, and increased general knowledge of the condition and its treatment options.
Further, the major countries studied in the market report are The US, Canada, the UK, Italy, Spain, China, Japan, India, German, France, Australia, South Korea, and Brazil.
Figure 2: HALITOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Halitosis Treatment. Due to rising oral hygiene awareness among people and rising diagnostic and therapeutic options for treating foul breath in several regional nations, the increasing prevalence of chronic illnesses like diabetes, respiratory conditions, and renal or liver failure with the growing population. Growing older adults with various conditions also contribute to the market's expansion. Furthermore, the German Halitosis Treatment market dominated, while the UK Halitosis Treatment market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Halitosis Treatment Market will develop at the quickest CAGR. A rise in knowledge about halitosis and the treatments available to cure it. Additionally, rising consumer desire for novel dental care products impacts market expansion. The region's residents make significant financial investments in healthcare, particularly dental care. Future growth of the market is predicted. Furthermore, China's Halitosis Treatment market had the highest market share, whereas India's Halitosis Treatment market was the Asia-Pacific region's fastest growing.
Halitosis Treatment Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Halitosis Treatment market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Halitosis Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Halitosis Treatment industry to serve clients and expand the market sector. The Halitosis Treatment industry has provided some of the most important benefits recently. Church & Dwight., Colgate-Palmolive, and other major companies in the Halitosis Treatment market are aiming to enhance market demand by investing in research and development activities
American consumer goods corporation Colgate-Palmolive has its main office on Park Avenue in Midtown Manhattan, New York City. Production, distribution, and provision of domestic, health, personal care, and veterinary items are the company's areas of expertise. The biggest manufacturer of soap and detergent in the world, Procter & Gamble (P&G), has long been a rival of Colgate-Palmolive. Following World War II, P&G launched their Tide laundry detergent, which attracted thousands of customers away from Colgate's soaps. When P&G introduced fluoride to their toothpaste, Colgate lost its top spot in the market (Colgate has subsequently reclaimed the top sales spot). In May 2021, In the United States, Colgate's Hello Products debuted fresh, natural, and eco-friendly oral care items like a reusable toothbrush, floss flavored with peppermint oil and coconut oil, tablets that freshen breath, and mouthwashes.
The market leader in home and personal care goods is Church & Dwight. ARM & HAMMER, Batiste, OxiClean, Trojan, XTRA, Nair, First Response, Spinbrush, Orajel, vita fusion, Li'l Critters, Water Pik, FLAWLESS, Zicam, and TheraBreath are just a few of our internationally recognized brands. They were established in 1846, operate internationally, and are included in the S&P 500. At Church & Dwight, they fuel people's daily lives by offering high-quality, cost-effective consumer goods. Where impact meets ambition is here. They are proud to be experts in our fields. Their team of highly skilled individuals innovates and concentrates on innovative methods. In November 2021, Church & Dwight Co., Inc. signed a legally binding contract to buy the TheraBreath name. TheraBreath is the second most popular brand of alcohol-free mouthwash in the US. Therefore, these advancements will probably help the market in North America flourish.
Key Companies in the Halitosis Treatment market include
Colgate-Palmolive Company (U.S)
All USA Partners LLC (U.S)
Dr. Harold Katz, LLC (U.S)
Rowpar Pharmaceuticals, Inc. (U.S)
Abbott (U.S)
Listerine (U.S)
AstraZeneca (U.S).
Halitosis Treatment Industry Developments
May 2022:The SmartMouth Mouth Sore Oral Rinse is the company's newest oral health innovation. With just two rinses each day, the new SmartMouth solution continues to prevent bad breath for 24 hours and is also designed to relieve mouth discomfort efficiently.
March 2022:Through its subsidiary Taiho Pharma Asia Pacific Pte. Ltd., Taiho Pharmaceutical Co., Ltd. (Japan) has introduced the PITAS throat troche series in Singapore. These film-type troches adhere to the roof of the mouth and are useful for treating throat discomfort and swelling.
Respiratory
Liver
Kidney
Gastrointestinal
Systemic
Others
Halimeter
Gas Chromatography
BANA Test
Β-Galactosidase Activity Assay
Others
Antacids
Antiseptics
Ranitidine
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
Report Attribute/Metric | Details |
Market Size 2022 | USD 3.9 Billion |
Market Size 2023 | USD 4.37 Billion |
Market Size 2032 | USD 10.91 Billion |
Compound Annual Growth Rate (CAGR) | 12.12% (2023-2032) |
Base Year | 2022 |
Market Forecast Period | 2023-2032 |
Historical Data | 2018- 2022 |
Market Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Drug Treatment, and Region |
Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled | Colgate-Palmolive Company (U.S), All USA Partners LLC (U.S), Dr. Harold Katz, LLC (U.S), Rowpar Pharmaceuticals, Inc. (U.S), Abbott (U.S), Listerine (U.S), AstraZeneca (U.S) |
Key Market Opportunities | Dental Health Care Products |
Key Market Dynamics | Rising incidence of periodontal disease |
The Halitosis Treatment market size was valued at USD 3.9 Billion in 2022.
The market is projected to grow at a CAGR of 12.12% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Colgate-Palmolive Company (U.S), All USA Partners LLC (U.S), Dr. Harold Katz, LLC (U.S), Rowpar Pharmaceuticals, Inc. (U.S),
The Liver dominated the market in 2022.
The antacids had the largest share in the market.
Key Questions Answered
Why Choose Market Research Future?